Table 2.
Virus/Strain | Cell Type | Compound | EC50 (µM) 1,2 | 95% CI (µM) | CC50 (µM) 1,2 | SI (CC50/EC50) |
---|---|---|---|---|---|---|
TBEV/Hypr | Vero | Diphyllin 1 | 0.85 | 0.47 to 1.42 | >100 | >117.64 |
TBEV/Hypr | Vero | Cleistanthin B 8 | 5.53 | 4.26 to 7.19 | >100 | >18.08 |
WNV/Eg-101 | Vero | Diphyllin 1 | 0.78 | 0.52 to 1.15 | >100 | >128.20 |
ZIKV/Paraiba_01 | Vero | Diphyllin 1 | 0.54 | 0.33 to 0.87 | >100 | >185.19 |
RVFV/H13/96 | Vero | Diphyllin 1 | 0.46 | 0.29 to 0.70 | >100 | >217.39 |
RABV/CVS-11 | BHK-21 | Diphyllin 1 | 6.33 | 2.86 to 14.90 | >100 | >15.80 |
HSV-1/MacIntyre | Vero | Diphyllin 1 | 0.59 | 0.35 to 0.96 | >100 | >169.49 |
1 Determined from three biological replicates of two independent experiments. 2 Expressed as a 50% reduction in viurs titer or cell viability as calculated at inflection points of sigmoidal virus titer or percentage cell viability curves, which were obtained by a nonlinear fit of transformed inhibitor concentrations versus normalized response using GraphPad Prism 7.04 (GraphPad Software, Inc., USA).